FinscoFinsco

Integra Lifesciences (US.IART)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.IART · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion16.7%↓
ROE-0.0%↑
Cash Conversion-→
D/E Ratio1.96→
Gross Margin53.9%↑
US.IART (Integra Lifesciences) | YoY: 2026 H1 vs 2025 H1


Metric           Value  YoY
---------------------------
FCF Conversion   16.7%    ↓
ROE              -0.0%    ↑
Cash Conversion      -    →
D/E Ratio         1.96    →
Gross Margin     53.9%    ↑
Key Metrics
US.IART (Integra Lifesciences) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
---------------------------
FCF Conversion 16.7% ↓
ROE -0.0% ↑
Cash Conversion - →
D/E Ratio 1.96 →
Gross Margin 53.9% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies